Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis.

The angiogenic process begins with the cell proliferation and migration into the primary vascular network, and leads to vascularization of previously avascular tissues and organs as well to growth and remodeling of the initially homogeneous capillary plexus to form a new microcirculation. Additionally, an increase in microvascular permeability is a crucial step in angiogenesis. Vascular endothelial growth factor (VEGF) plays a central role in angiogenesis. We have previously reported that albendazole suppresses VEGF levels and inhibits malignant ascites formation, suggesting a possible effect on angiogenesis. This study was therefore designed to investigate the antiangiogenic effect of albendazole in non-cancerous models of angiogenesis. In vitro, treatment of human umbilical vein endothelial cells (HUVECs) with albendazole led to inhibition of tube formation, migration, permeability and down-regulation of the VEGF type 2 receptor (VEGFR-2). In vivo albendazole profoundly inhibited hyperoxia-induced retinal angiogenesis in mice. These results provide new insights into the antiangiogenic effects of albendazole.

[1]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[2]  S. Harper,et al.  Regulation of vascular permeability by vascular endothelial growth factors. , 2002, Vascular pharmacology.

[3]  D. Ribatti,et al.  Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 1999 .

[4]  Lois E. H. Smith,et al.  Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.

[5]  D. Morris,et al.  Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. , 2007, Biochemical pharmacology.

[6]  Jack A Roth,et al.  Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  G. Krissansen,et al.  Antisense HIF-1α prevents acquired tumor resistance to angiostatin gene therapy , 2010, Cancer Gene Therapy.

[8]  G. Godlewski,et al.  Poly(ADP‐ribose)polymerase inhibition decreases angiogenesis. , 2006, Biochemical and biophysical research communications.

[9]  M. Poruchynsky,et al.  Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole , 2010, BMC Cancer.

[10]  Lisa I. Wang,et al.  Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis , 2005, Cancer Chemotherapy and Pharmacology.

[11]  M. Links,et al.  Inhibition of Cell Proliferation, Vascular Endothelial Growth Factor and Tumor Growth by Albendazole , 2009, Cancer investigation.

[12]  Ettenson Ds,et al.  Centrosomes, microtubules, and microfilaments in the reendothelialization and remodeling of double-sided in vitro wounds. , 1992 .

[13]  Napoleone Ferrara,et al.  Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. , 2005, Biochemical and biophysical research communications.

[14]  R. C. Parish,et al.  Anthelmintic activity of albendazole against liver flukes, tapeworms, lung and gastrointestinal roundworms , 1976, Experientia.

[15]  F. Piscione,et al.  Endothelial α1‐adrenoceptors regulate neo‐angiogenesis , 2008 .

[16]  Giovanni Mazzoni,et al.  Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice , 2008, Cancer Chemotherapy and Pharmacology.

[17]  I. Herman,et al.  Mechanisms of normal and tumor-derived angiogenesis. , 2002, American journal of physiology. Cell physiology.

[18]  E. Lacey,et al.  Structure-activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin, in vitro. , 1985, Biochemical pharmacology.

[19]  K. Suzuma,et al.  EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. , 2006, The American journal of pathology.

[20]  D. Morris,et al.  In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. , 2001, Cancer letters.

[21]  Nicodemus Tedla,et al.  Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun , 2006, Nature Biotechnology.

[22]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[23]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[24]  M. Karkkainen,et al.  Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis , 2000, Oncogene.

[25]  J. Horton Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations , 2002, Current opinion in infectious diseases.

[26]  Napoleone Ferrara,et al.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.

[27]  M. De Brabander,et al.  Influence of the anthelmintic mebendazole on microtubules and intracellular organelle movement in nematode intestinal cells. , 1975, American journal of veterinary research.

[28]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  N. Awasthi,et al.  Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling , 2009, Laboratory Investigation.

[30]  T. Gardner,et al.  Retinal angiogenesis in development and disease , 2005, Nature.

[31]  M. Meissner,et al.  Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms. , 2008, The Journal of investigative dermatology.

[32]  H. Dvorak,et al.  Vascular permeability, vascular hyperpermeability and angiogenesis , 2008, Angiogenesis.

[33]  Jack A Roth,et al.  The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. , 2002, Molecular cancer therapeutics.

[34]  Lisa I. Wang,et al.  Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice , 2006, Clinical Cancer Research.

[35]  L. Liaudet,et al.  Serveur Académique Lausannois SERVAL serval.unil.ch , 2022 .

[36]  N. Hay,et al.  Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo , 2005, Nature Medicine.

[37]  B. Lal,et al.  VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. , 2001, Microvascular research.